Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113549 | 1.00 | KCNH2 (0.37) | KCNH2P2RX3OPRK1SOS1MAPT | |
| SCHEMBL2114696 | 0.91 | P2RX3 (0.38) | KCNH2P2RX3OPRK1SOS1 | |
| SCHEMBL2114702 | 0.91 | P2RX3 (0.38) | KCNH2P2RX3OPRK1SOS1 | |
| SCHEMBL2113556 | 0.90 | P2RX3 (0.35) | P2RX3OPRK1MAPTLMNA | |
| SCHEMBL2113554 | 0.90 | P2RX3 (0.35) | P2RX3OPRK1MAPTLMNA | |
| SCHEMBL2114085 | 0.90 | OPRK1 (0.34) | P2RX3OPRK1SOS1 | |
| SCHEMBL2115728 | 0.89 | OPRK1 (0.38) | OPRK1KDM4EUSP2HSD17B10 | |
| SCHEMBL2113805 | 0.89 | P2RX3 (0.34) | KCNH2P2RX3OPRK1SOS1 | |
| SCHEMBL2115362 | 0.89 | OPRK1 (0.34) | P2RX3OPRK1 | |
| SCHEMBL2117046 | 0.89 | TP53 (0.35) | P2RX3OPRK1SOS1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | claimed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | KCNH2 738/4885P2RX3 123/4885OPRK1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.